eXoZymes (EXOZ) Q4 2025 earnings review
Losses Widen and Cash Dwindles as eXoZymes Races Against the Clock
eXoZymes, a development-stage biomanufacturing company, remains pre-revenue as it pivots toward high-value targets like its NCT metabolic program. While management touts the scientific validation of its cell-free "exozyme" platform, the financial reality is stark. Net loss widened by 56% to $9.16 million in FY25 as R&D costs nearly doubled. With only $3.04 million in cash remaining, the company expects funding to last only until the middle of Q2 2026. An imminent financing round is urgently required to keep the lights on.
🐂 Bull Case
NCT has advanced from concept to pilot-scale readiness in less than a year with >99% purity. Preclinical trials yielded strong metabolic efficacy, including a 30-40% body weight reduction in mice.
By executing bioconversion cell-free, eXoZymes avoids the massive scaling bottlenecks and cellular toxicity constraints that caused the collapse of prior synthetic biology pioneers.
🐻 Bear Case
With a going concern warning and cash to survive only until mid-Q2 2026, the company is highly dependent on securing rapid financing.
Commercialization of its first products is still in early pilot stages. Regulatory paths for both nutraceutical and pharmaceutical applications have unknown outcomes and long timelines.
⚖️ Verdict: 🔴
Bearish. Despite intriguing technology and quick pilot-scale progression on NCT, the company is burning cash rapidly and has limited runway. Investors face imminent dilution risk from the upcoming fundraising cycle.
Key Themes
Going Concern Warning as Runway Shortens
The company’s cash dropped from $9.72 million to just $3.04 million in 2025. Management has explicitly issued a substantial doubt about its ability to continue as a going concern, anticipating funding shortfalls. The current cash balance supports operations only into the middle of Q2 2026. This trajectory is Accelerating toward empty without an imminent financing bridge.
Costs Surge While Grant Offsets Decline
In a troubling divergence from management's positive framing of grant support, the actual grants offset against R&D fell by $0.67 million to $1.57 million in 2025. Simultaneously, R&D expenses gross of grants surged to $5.31 million. This lack of external subsidization directly accelerated the widening net loss, contradicting the narrative of high capital efficiency.
Focusing on NCT Commercialization
In response to difficult market dynamics, eXoZymes shifted from a wide partnership search to advancing its N-trans-caffeoyltyramine (NCT) small molecule program. NCT acts on the body’s master metabolic switch. The goal is a dual-track commercialization: establishing a low-barrier nutraceutical ingredient line and higher-barrier pharmaceutical analogs.
Moving Beyond Living Cells with 'Exozymes'
To remove confusion about its methodology, the company rebranded from Invizyne to eXoZymes in February 2025. The platform liberates enzymes from living cells, performing pure multi-step enzymatic cascades in a single pot. This enables 6x faster production cycles and predictable single-product precision with yields exceeding 99%.
Diverse Subsidiary and Grant Backing
The company established a specific entity, NCTx, to drive its main metabolic candidate forward. It also retains active government-funded initiatives, including a cost-share grant from the DoD BioMADE initiative for cell-free biomanufacturing of isobutanol to be utilized in Sustainable Aviation Fuels.
Macro Environment Squeezing Financing Access
The company notes that inflationary pressures and broader indications of an economic recession could restrict access to capital markets. Given that eXoZymes relies entirely on financing to fund operations, unfavorable macro conditions could impede the timing and favorable pricing of its next equity raise.
Other KPIs
G&A costs were Accelerating, growing 48% due to higher administrative staffing not covered by grants, Nasdaq compliance fees following the 2024 IPO, and director fees.
R&D costs nearly doubled from $1.87 million to $3.71 million (net of grant offsets), reflecting an aggressive push to transfer its NCT process to external pilot plant operators.
Decelerating from $0.74 million in 2024, representing the timing of grant drawdowns and the wind-down of completed legacy grants.
Guidance
The company provided no quantitative full-year financial guidance but guided that current cash and cash equivalents are only sufficient to fund operations to the middle of Q2 2026. This represents a Reversing cash cushion that necessitates immediate capital injection.
Key Questions
Imminent Financing Details
Management noted that the company is actively in roadshows for an imminent financing round. What are the expected terms, and will it be dilutive to current minority shareholders?
Decline in Grant Offsets
Why did the actual grant amounts offset against R&D costs decline significantly in FY25 despite the reported acquisition of new NIH and DoD awards?
NCT Commercialization Timeline
When does management expect the first commercial sales or licensing milestones of NCT to generate tangible revenue to stem the cash burn?